A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2019
Price : $35 *
At a glance
- Drugs APG-2575 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 14 Jul 2019 Preliminary results presented in an Ascentage Pharma Media Release.
- 14 Jul 2019 According to an Ascentage Pharma media release, at present, 4 dose cohorts have been completed in the United States and Australia.
- 13 Aug 2018 Status changed from not yet recruiting to recruiting.